{"product_id":"ptgx-marketing-mix","title":"(PTGX) Protagonist Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Protagonist Therapeutics, Inc. 4P's Marketing Mix Analysis outlines the company’s product offerings, pricing strategy, distribution channels, and promotional tactics to show how it competes in specialty therapeutics — the page includes a real preview\/sample of the analysis so you can assess style and content; purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics has no approved commercial products, so its product mix is still built around pipeline assets and platform research. That means development milestones, not drug sales, drive value; in FY2025, product revenue was $0, with income coming from collaboration and other non-product sources. This keeps the story tied to clinical progress in programs like rusfertide and JAK inhibition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRusfertide PTG-300\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRusfertide (PTG-300) is Protagonist Therapeutics, Inc.’s lead hematology asset and its most advanced pipeline program, with studies in polycythemia vera, hereditary hemochromatosis, and other blood disorders. As an injectable hepcidin mimetic, it lowers iron availability to help curb excess red blood cell production, a core driver in these diseases. In marketing terms, its strongest pull is clear clinical need and broad hematology use, while its late-stage status gives the product high strategic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePN-943 oral peptide\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePN-943 is an oral peptide in Protagonist Therapeutics, Inc. immune-mediated disease pipeline, designed as a selective alpha-4-beta-7 integrin antagonist for inflammatory bowel disease. The aim is gut-selective immune control with oral dosing, which could improve convenience versus injected biologics. In 2025, it remained a clinical-stage asset with no reported product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePN-235 oral IL-23R antagonist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePN-235 is an oral peptide IL-23R antagonist in Protagonist Therapeutics, Inc.'s pipeline for IBD and possible non-IBD use. It broadens the Company Name's immunology reach beyond alpha-4-beta-7 biology and supports a wider inflammation strategy. One key point: it gives the pipeline a second, distinct immune target.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eOral peptide; receptor-based mechanism\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTargets IBD and broader inflammation use\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExpands beyond alpha-4-beta-7 biology\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeptide-based discovery platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. builds its core product engine on peptide-based discovery, using engineered peptides to generate repeatable candidates in hematology and immune disease. Its lead asset, rusfertide, advanced into Phase 3 VERIFY for polycythemia vera in 2024, showing the platform can move from science to late-stage assets. That makes the mix both asset-led and technology-led, with one discovery engine feeding multiple indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngineered peptides drive the pipeline.\u003c\/li\u003e\n\u003cli\u003eRusfertide anchors late-stage value.\u003c\/li\u003e\n\u003cli\u003eSame platform supports multiple targets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtagonist’s Value Hinges on Late-Stage Pipeline Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. has no approved products, so Product is still pipeline-led. FY2025 product revenue was $0, and value rests on late-stage assets like rusfertide plus oral peptide programs PN-943 and PN-235. The mix is narrow but focused: hematology and immunology, with one platform feeding several targets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRusfertide\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eLead hematology asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePN-943\u003c\/td\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eIBD candidate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePN-235\u003c\/td\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eImmune pipeline broadener\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific deep dive into Protagonist Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDistills Protagonist Therapeutics’ 4Ps into a quick, decision-ready snapshot for faster biotech strategy reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, clinical trial registries, SEC filings, and peer-reviewed studies to let investors verify Protagonist Therapeutics’ market, pricing, and clinical assumptions quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNewark California headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. is headquartered in Newark, California, and that site anchors corporate leadership, research coordination, and strategic decision-making. It is the company’s main operating base, with 2025 revenue of $0.0 million and no broad retail distribution footprint. The Newark location supports a lean, research-led model rather than a store-based one.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial site network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. uses a clinical trial site network, not stores, to reach patients. Its candidates are given only under controlled multicenter study protocols, so this channel is research-led and still the main route to product access before any commercial launch. In 2025, that model kept distribution tied to trial enrollment and site oversight, not consumer demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnered development channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. uses its licensing and collaborative deal with Janssen Biotech, Inc. to push selected programs through an external development and commercialization path. That setup broadens reach beyond Protagonist Therapeutics, Inc.’s internal team and can lower the need for a full in-house sales force at this stage. It also lets Protagonist Therapeutics, Inc. share execution risk while keeping focus on pipeline work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnited States focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. is U.S.-based and headquartered in Newark, California, so its development, finance, and corporate work are centered in the United States. That fits a late-stage biotech model, where the key job is running U.S. clinical and regulatory work first. In 2025, the Company kept its core pipeline tied to U.S. trial sites and FDA pathways, which is the usual launch path for a U.S. biotech.\u003c\/p\u003e\n\u003cp\u003eAny first launch would likely start in the United States and other major regulated markets such as the EU and Japan, after approval. The U.S. market also gives Protagonist Therapeutics, Inc. direct access to top hospitals, trial investigators, and payers, which matters for a specialty drug rollout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeadquarters: Newark, California\u003c\/li\u003e\n\u003cli\u003ePrimary focus: United States\u003c\/li\u003e\n\u003cli\u003eLaunch path: FDA first\u003c\/li\u003e\n\u003cli\u003eNext markets: EU and Japan\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo commercial distribution yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. has no approved products as of FY2025, so there is no traditional commercial distribution channel. That means no retail, hospital, or pharmacy network is carrying sales today, and access stays limited to clinical trials, research ties, and corporate collaborations. So its place strategy is still pre-commercial.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNo approved products, no product sales.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNo retail, hospital, or pharmacy channel.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAccess comes through trials and partnerships.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePlace strategy remains pre-commercial.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtagonist’s Reach Stays Clinical, Collaborative, and Pre-Commercial\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. keeps its Place strategy centered on Newark, California, and on U.S. clinical trial sites, not on a retail network. With FY2025 revenue of $0.0 million and no approved products, access stayed pre-commercial and research-led. Its Janssen Biotech, Inc. collaboration also extends reach without building a full sales footprint.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace metric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadquarters\u003c\/td\u003e\n\u003ctd\u003eNewark, California\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$0.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess channel\u003c\/td\u003e\n\u003ctd\u003eClinical trials and partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eProtagonist Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Protagonist Therapeutics, Inc. 4P's Marketing Mix document you’ll receive instantly after purchase—fully detailed and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis is not a sample or demo; you’re viewing the exact editable analysis included with your order, with product, price, place, and promotion insights tailored to Protagonist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. promotes Clinical data announcements through trial readouts and pipeline updates, not consumer ads. For a clinical-stage biotech, this is the main way to build awareness and can move valuation, partnering talks, and FDA momentum. The message is evidence-led: positive phase data can change how investors price the pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics uses scientific congresses to show mechanism and efficacy data to clinicians, researchers, and industry analysts, which matters most in niche and specialty therapies. These meetings can reach thousands of HCPs and researchers in one setting, helping a small-cap biopharma stretch each launch dollar. In 2025, that kind of peer-reviewed visibility is a low-cost way to build trust before commercial scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Protagonist Therapeutics, Inc. used earnings calls, press releases, and 10-K\/10-Q filings to track pipeline milestones and strategy for investors. With no product sales, its promotion is aimed mainly at capital markets, which is standard for a biotech before commercialization. That keeps focus on clinical data, cash use, and partnership updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership disclosure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnership disclosure is a key promotion lever for Protagonist Therapeutics, Inc., and Janssen Biotech news acts as third-party validation of the platform. Such updates can widen reach with clinicians, partners, and investors, since biotech partner announcements often do more to build trust than paid ads.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJanssen ties signal external validation.\u003c\/li\u003e\n\u003cli\u003ePartner news expands market attention.\u003c\/li\u003e\n\u003cli\u003eCredibility is a core biotech asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo consumer mass advertising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. does not use broad consumer mass advertising because it still has no marketed prescription products. Its 2025 promotion stayed B2B focused, aimed at physicians, regulators, investors, and strategic partners rather than patients. That means the message is technical, clinical, and tied to pipeline progress, not consumer brand building.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo consumer ad spend\u003c\/li\u003e\n\u003cli\u003eAudience: doctors and regulators\u003c\/li\u003e\n\u003cli\u003ePromotion tracks pipeline updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtagonist’s FY2025 B2B Promo Built Pipeline Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. promotion in FY2025 was B2B, not consumer-led: it used trial readouts, congress talks, press releases, and SEC filings to reach investors, clinicians, regulators, and partners. With no marketed products, its main goal was to build trust in the pipeline and support valuation. Janssen Biotech updates added third-party validation and widened attention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 channel\u003c\/th\u003e\n\u003cth\u003eMain audience\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial readouts\u003c\/td\u003e\n\u003ctd\u003eInvestors, HCPs\u003c\/td\u003e\n\u003ctd\u003ePipeline proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongress updates\u003c\/td\u003e\n\u003ctd\u003eResearchers\u003c\/td\u003e\n\u003ctd\u003eScientific credibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner news\u003c\/td\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eValidation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo commercial drug price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics has no approved commercial drug, so there is no public list price or revenue price today. Its pipeline candidates are not sold directly to patients, and pricing only matters after FDA approval. In its 2025 annual reporting, Protagonist still had no product sales, so price is not yet a market lever.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-based future pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved, Protagonist Therapeutics, Inc. would likely price on specialty-drug value, with payer leverage tied to clinical gain, disease severity, and unmet need. In polycythemia vera, rusfertide’s Phase 3 VERIFY data showed hematocrit control in 77% of patients vs 32% on placebo, a strong value anchor. IBD also faces tight reimbursement scrutiny, so payer evidence will drive pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral and injectable mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRusfertide is a once-weekly injectable, while PN-943 and PN-235 are oral peptides. That split matters on price: injectables can support stronger reimbursement if they cut clinic use or phlebotomy, while oral specialty drugs must win on convenience and adherence. As of FY2025, Protagonist Therapeutics still had 0 product sales, so pricing power remains pipeline-driven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement dependent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAny eventual Protagonist Therapeutics, Inc. price would be reimbursement dependent, because payer coverage and formulary access usually set real net price in biopharma.\u003c\/p\u003e\n\u003cp\u003eIn chronic hematology and inflammatory diseases, premium pricing only holds when clinical benefit is clear enough to win insurer and health-system negotiations; otherwise rebates and step edits compress value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage drives net price\u003c\/li\u003e\n\u003cli\u003eFormularies shape access\u003c\/li\u003e\n\u003cli\u003eDifferentiation supports premium\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. does not rely on price alone: its Janssen deal can add upfront cash, milestones, royalties, and cost sharing. The collaboration was announced with a $50 million upfront payment and up to $1.7 billion in potential milestones, so net realized revenue can diverge sharply from gross product price.\u003c\/p\u003e\n\u003cp\u003eFor a development-stage Company, that means deal terms can matter more than end-user pricing. Even a high launch price can leave less value if royalties are low or development costs are shared heavily.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront cash boosts near-term funding\u003c\/li\u003e\n\u003cli\u003eMilestones can outweigh launch price\u003c\/li\u003e\n\u003cli\u003eRoyalties shape long-term net revenue\u003c\/li\u003e\n\u003cli\u003eCost sharing cuts Protagonist Therapeutics, Inc. burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtagonist’s Price Is Pipeline-Driven as Rusfertide Nears Approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProtagonist Therapeutics, Inc. has no approved product sales in FY2025, so Price is still pipeline-based, not market-based. Rusfertide’s Phase 3 VERIFY data showed 77% hematocrit control vs 32% placebo, which could support premium specialty-drug pricing if approved. Any net price will hinge on payer coverage, rebates, and formulary access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 price signal\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVERIFY hematocrit control\u003c\/td\u003e\n\u003ctd\u003e77% vs 32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen upfront\u003c\/td\u003e\n\u003ctd\u003e$50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential milestones\u003c\/td\u003e\n\u003ctd\u003eUp to $1.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234912968969,"sku":"ptgx-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ptgx-marketing-mix.webp?v=1785729322","url":"https:\/\/dcfanalyst.com\/products\/ptgx-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}